Hoffman Lauren K, Raymond Isabelle, Kircik Leon
J Drugs Dermatol. 2018 Feb 1;17(2):229-232.
Tinea pedis is the most common dermatophyte infection. Treatment is critical to alleviate pruritic symptoms, to reduce the risk for secondary bacterial infection, and to limit the spread of infection to other body sites or other individuals. The objective of this study was to compare the abilities of econazole nitrate topical foam, 1% and ketoconazole cream (2%) to reduce pruritus, thus improving quality of life, and to determine patient preference for the foam product versus the cream product in patients with interdigital tinea pedis.
A single-center, investigator-blinded, observational pilot study was conducted to compare econazole nitrate topical foam (1%) to ketoconazole cream (2%). In this split-body study, 20 subjects received both econazole nitrate topical foam and ketoconazole cream and applied the medications daily to either the right or left foot for 14 days. Improvements in patient quality of life (pruritus) and patient preference were measured using the pruritus visual analog scale (VAS), Skindex-16, and patient preference questionnaires.
Nineteen subjects completed the study and one subject was lost to follow-up. Reductions in VAS scores of econazole nitrate topical foam were significantly greater than those of ketoconazole cream, indicating the superiority of the econazole nitrate foam in reducing pruritus. Skindex-16 data showed significant reductions in total scores and individual domains, including patient symptom, emotional, and functional domains, by the final visit. Since each subject received both medications the questionnaire was not medication-specific. Responses to patient preference questionnaires showed that econazole nitrate topical foam,1% was rated as "good" or "excellent" in all measures assessed. One adverse event was noted.
In patients with interdigital tinea pedis, application of econazole nitrate topical foam 1% twice daily for two weeks was clinically effective and significantly superior to ketoconazole cream 2% in reducing pruritus. J Drugs Dermatol. 2018;17(2):229-232.
足癣是最常见的皮肤癣菌感染。治疗对于缓解瘙痒症状、降低继发细菌感染风险以及限制感染传播至身体其他部位或其他个体至关重要。本研究的目的是比较硝酸益康唑外用泡沫(1%)和酮康唑乳膏(2%)减轻瘙痒从而改善生活质量的能力,并确定患有指间足癣的患者对泡沫产品与乳膏产品的偏好。
进行了一项单中心、研究者设盲的观察性试点研究,以比较硝酸益康唑外用泡沫(1%)和酮康唑乳膏(2%)。在这项双侧研究中,20名受试者同时接受硝酸益康唑外用泡沫和酮康唑乳膏,并将药物每日应用于右脚或左脚,持续14天。使用瘙痒视觉模拟量表(VAS)、Skindex - 16和患者偏好问卷来衡量患者生活质量(瘙痒)的改善情况和患者偏好。
19名受试者完成了研究,1名受试者失访。硝酸益康唑外用泡沫的VAS评分降低幅度显著大于酮康唑乳膏,表明硝酸益康唑泡沫在减轻瘙痒方面具有优越性。Skindex - 16数据显示,到最后一次访视时,总分及各个领域,包括患者症状、情感和功能领域的得分均显著降低。由于每位受试者都接受了两种药物治疗,问卷并非针对特定药物。对患者偏好问卷的回答显示,1%的硝酸益康唑外用泡沫在所有评估指标中均被评为“良好”或“优秀”。记录到1例不良事件。
对于患有指间足癣的患者,每日两次应用1%的硝酸益康唑外用泡沫,持续两周,在减轻瘙痒方面临床有效且显著优于2%的酮康唑乳膏。《药物皮肤病学杂志》。2018年;17(2):229 - 232。